ATE474597T1 - Inhibition des migrations-inhibitions-faktors in der behandlung von krankheiten bei denen eine cytokin-vermittelte toxizität eine rolle spielt - Google Patents

Inhibition des migrations-inhibitions-faktors in der behandlung von krankheiten bei denen eine cytokin-vermittelte toxizität eine rolle spielt

Info

Publication number
ATE474597T1
ATE474597T1 AT94916785T AT94916785T ATE474597T1 AT E474597 T1 ATE474597 T1 AT E474597T1 AT 94916785 T AT94916785 T AT 94916785T AT 94916785 T AT94916785 T AT 94916785T AT E474597 T1 ATE474597 T1 AT E474597T1
Authority
AT
Austria
Prior art keywords
inhibition
treatment
cytokine
diseases
role
Prior art date
Application number
AT94916785T
Other languages
English (en)
Inventor
Richard J Bucala
Robert A Mitchell
Jurgen Bernhagen
Thierry F Calandra
Anthony Cerami
Original Assignee
Cytokine Pharmasciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokine Pharmasciences Inc filed Critical Cytokine Pharmasciences Inc
Application granted granted Critical
Publication of ATE474597T1 publication Critical patent/ATE474597T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0325—Animal model for autoimmune diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0368—Animal model for inflammation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
AT94916785T 1993-05-17 1994-05-16 Inhibition des migrations-inhibitions-faktors in der behandlung von krankheiten bei denen eine cytokin-vermittelte toxizität eine rolle spielt ATE474597T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6339993A 1993-05-17 1993-05-17
PCT/US1994/005433 WO1994026307A1 (en) 1993-05-17 1994-05-16 Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity

Publications (1)

Publication Number Publication Date
ATE474597T1 true ATE474597T1 (de) 2010-08-15

Family

ID=22048950

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94916785T ATE474597T1 (de) 1993-05-17 1994-05-16 Inhibition des migrations-inhibitions-faktors in der behandlung von krankheiten bei denen eine cytokin-vermittelte toxizität eine rolle spielt

Country Status (7)

Country Link
EP (2) EP0702566B1 (de)
JP (1) JP4708510B2 (de)
AT (1) ATE474597T1 (de)
AU (1) AU692159B2 (de)
CA (1) CA2163211C (de)
DE (1) DE69435303D1 (de)
WO (1) WO1994026307A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6863890B1 (en) * 1993-02-26 2005-03-08 Advanced Biotherapy, Inc. Treatment of AIDS with antibodies to gamma interferon, alpha interferon and TNF-alpha
JP3578787B2 (ja) * 1993-05-14 2004-10-20 ラホヤ インスティチュート フォア アレルギー アンド イムノロジー 生物学的に活性なポリペプチドの組換え製造方法
US6774227B1 (en) * 1993-05-17 2004-08-10 Cytokine Pharmasciences, Inc. Therapeutic uses of factors which inhibit or neutralize MIF activity
SI9400363A (en) * 1994-09-19 1996-08-31 Mozetic Francky Bojana Human macrophage migration inhibitory factor of nonlymphoid origin, expression of mif in e. coli and purification of recombinant protein
WO1996015242A2 (en) * 1994-11-16 1996-05-23 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods for inhibiting cell proliferation by inhibiting the mitogenic activity of macrophage migration inhibitory factor
US5910427A (en) * 1995-06-22 1999-06-08 La Jolla Institute For Allergy And Immunology Antigen non-specific glycosylation inhibiting factor derivatives
US6420188B1 (en) * 1996-02-16 2002-07-16 The Picower Institute For Medical Research Screening assay for the identification of inhibitors for macrophage migration inhibitory factor
CA2361590C (en) 1999-02-05 2011-03-22 Rina Das Method of diagnosing of exposure to toxic agents by measuring distinct pattern in the levels of expression of specific genes
ATE473294T1 (de) * 2001-03-29 2010-07-15 Cytokine Pharmasciences Inc Verfahren und zusammensetzungen zur verwendung von mhc-klasse ii-invariante-kette-polypeptid als rezeptor für makrophagenwanderung-hemmfaktor
UY27304A1 (es) 2001-05-24 2002-12-31 Avanir Pharmaceuticals Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación
US20060034832A1 (en) 2002-04-26 2006-02-16 Haruhide Kimura Cell death inhibitor
US7105336B2 (en) * 2002-10-07 2006-09-12 Biogaia Ab Selection and use of lactic acid bacteria for reducing inflammation caused by Helicobacter
TW200418829A (en) 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
WO2005021546A1 (en) 2003-08-22 2005-03-10 Avanir Pharmaceuticals Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases
WO2005058304A1 (en) * 2003-12-17 2005-06-30 Cortical Pty Ltd Implantable device containing inhibitor of macrophage migration inhibitory factor
AU2005313971B2 (en) 2004-12-08 2011-10-13 Immunomedics, Inc. Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
EP1861407A1 (de) 2005-03-24 2007-12-05 Avanir Pharmaceuticals Thienopyridinonderivate als hemmer des makrophagenmigrationshemmfaktors
JP5129122B2 (ja) * 2005-04-26 2013-01-23 トリオン ファーマ ゲーエムベーハー 癌治療のための抗体およびグルココルチコイドの組み合わせ
US20110044988A1 (en) * 2008-03-20 2011-02-24 Carolus Therpeutics, Inc. Methods of treatment using anti-mif antibodies
JP2014526886A (ja) 2011-07-15 2014-10-09 モルフォシス・アー・ゲー マクロファージ遊走阻止因子（ｍｉｆ）とｄ−ドーパクロームトートメラーゼ（ｄ−ｄｔ）に交差反応性がある抗体
JP2014530361A (ja) * 2011-10-07 2014-11-17 バクスター・ヘルスケヤー・ソシエテ・アノニムＢａｘｔｅｒ Ｈｅａｌｔｈｃａｒｅ ＳＡ Ｃｈｏ−ｍｉｆ遺伝子およびタンパク質の特性評価およびその使用
US9958456B2 (en) 2011-10-07 2018-05-01 Baxalta Incorporated OxMIF as a diagnostic marker
AU2013203957B9 (en) * 2012-04-16 2015-10-15 Baxalta GmbH Combination Therapy of Anti-MIF Antibodies and Glucocorticoids
AU2013202693B2 (en) * 2012-04-16 2015-01-22 Baxalta GmbH Combination Therapy of Anti-MIF Antibodies and Chemotherapeutics
JP2012254994A (ja) * 2012-07-23 2012-12-27 Trion Pharma Gmbh 癌治療のための抗体およびグルココルチコイドの組み合わせ
CN114317666A (zh) * 2021-11-25 2022-04-12 中国科学院生态环境研究中心 环境污染物的免疫毒性的检测方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
DD230876A1 (de) * 1983-05-09 1985-12-11 Akad Wissenschaften Ddr Verfahren zur gewinnung monoklonaler antikoerper gegen human-mif
JPH0672158B2 (ja) * 1984-05-24 1994-09-14 チバ−ガイギ− アクチエンゲゼルシヤフト 精製されたヒトマクロファージ遊走阻止因子
US4708937A (en) * 1984-10-15 1987-11-24 Brigham & Women's Hospital Purified migration inhibitory factor also having colony stimulating factor activity
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules

Also Published As

Publication number Publication date
CA2163211C (en) 2012-05-08
WO1994026307A1 (en) 1994-11-24
EP0702566A1 (de) 1996-03-27
EP0702566A4 (de) 1997-02-26
EP1741779A3 (de) 2010-03-24
JP4708510B2 (ja) 2011-06-22
CA2163211A1 (en) 1994-11-24
DE69435303D1 (de) 2010-09-02
AU6834594A (en) 1994-12-12
EP1741779A2 (de) 2007-01-10
AU692159B2 (en) 1998-06-04
JPH09500363A (ja) 1997-01-14
EP0702566B1 (de) 2010-07-21

Similar Documents

Publication Publication Date Title
ATE474597T1 (de) Inhibition des migrations-inhibitions-faktors in der behandlung von krankheiten bei denen eine cytokin-vermittelte toxizität eine rolle spielt
ATE185548T1 (de) Verwendung von n-arylmethylen ethylendiamintriacetate, n-arylmethylen iminodiacetat oder n,n'-diarylmethylen ethylendiamindiacetat gegen oxidativen stress
BG101841A (bg) Инхибитори на клетъчна адхезия
MX9101869A (es) Ciclosporinas, composicion farmaceutica que las contiene y procedimiento para la produccion de las mismas
BG102872A (en) 6-phenylpyridyl-3-amine derivatives
ATE198983T1 (de) Verfahren zur inhibierung von aldh-i zur behandlung von alkoholabhaengigkeit oder- missbrauch
DE69109560D1 (de) Fungizide Zusammensetzung zur Behandlung von Saatgut.
EP0840608A4 (de) Behandlung und vorbeugung von neoplasmen mit salzen von aminoimidazolcarboxamid und 5-amino-oder substituierten amino 1,2,3-triazolen
BG104599A (en) Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas
NO961326D0 (no) Inhibitorer av
TNSN00010A1 (fr) DIPHENYLUREE A SUBSTITUTION ω CARBOXYARYLE SERVANT D'INHIBUTEURS DE RAF KINASE.
ATE262895T1 (de) Verwendung von hemmern des maillard-reaktion zur behandlung von krankheiten zufolge amyloidosis
FR2786664B1 (fr) Procede de traitement de fruits et legumes utilisant l'eugenol et/ou l'isoeugenol et utilisation d'une composition a base d'eugenol et/ou d'isoeugenol
DE69109583D1 (de) Verfahren zur Behandlung von entzündlichen Darmerkrankungen.
ATE103918T1 (de) 5,11-dihydro-6h-dipyrido(3,2-b:2',3'e>(1,4>diazepin-6-one und -thione und ihre verwendung bei der aids-vorbeugung oder behandlung.
ATE412419T1 (de) Verwendung von poly-glu, tyr zur neuroprotektiven therapie des zns oder pns
HU9501146D0 (en) 2-amino-4-phenyl-4-oxo-butyric acid derivatives with kynureninase and/or kynurenine-3-hydroxylase inhibiting activity
GR3022765T3 (en) Arylamidoalkyl- and arylaminoalkyl-n-hydroxyurea compounds and -n-hydroxyformamide derivatives having lipoxygenase inhibitory activity
DE69425820D1 (de) Verwendung von ferrioxamin-b zur behandlung septischen schocks
WO1998032428A3 (en) Compositions comprising choline and use of choline to treat endotoxic shock
EP0303681A4 (de) Immunosuppression bei der auf immunotoxin basierten behandlung von menschen.
RU93056841A (ru) Способы лечения и защиты позвоночных от паразитов, композиции на основе дисульфонилметанов для борьбы с паразитами, новые соединения
DE69424679D1 (de) Zusammensetzung zur behandlung oder vorbeugung von herpes
DE69023006D1 (de) Verfahren zur behandlung von thrombocytopenie und dafür geeignete pharmazeutische zusammensetzungen.
PT971714E (pt) Metodo utilizando inibidores ciclooxigenase-2 no tratamento e prevencao da demencia

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties